AU6233501A - Nucleic acid molecule comprising a nucleic acid sequence coding for an sdf-1 gamma chemokine, a neuropeptide precursor or at least one neuropeptide - Google Patents

Nucleic acid molecule comprising a nucleic acid sequence coding for an sdf-1 gamma chemokine, a neuropeptide precursor or at least one neuropeptide

Info

Publication number
AU6233501A
AU6233501A AU62335/01A AU6233501A AU6233501A AU 6233501 A AU6233501 A AU 6233501A AU 62335/01 A AU62335/01 A AU 62335/01A AU 6233501 A AU6233501 A AU 6233501A AU 6233501 A AU6233501 A AU 6233501A
Authority
AU
Australia
Prior art keywords
neuropeptide
nucleic acid
sdf
acid molecule
sequence coding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU62335/01A
Other languages
English (en)
Inventor
Johannes Auer
Frank Bosse
Clemens Gillen
Marc Gleichmann
Hans-Werner Muller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dynavax GmbH
Original Assignee
Rhein Biotech GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhein Biotech GmbH filed Critical Rhein Biotech GmbH
Publication of AU6233501A publication Critical patent/AU6233501A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU62335/01A 2000-06-02 2001-06-01 Nucleic acid molecule comprising a nucleic acid sequence coding for an sdf-1 gamma chemokine, a neuropeptide precursor or at least one neuropeptide Abandoned AU6233501A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10027383A DE10027383A1 (de) 2000-06-02 2000-06-02 Nukleinsäure-Molekül umfassend eine für ein Chemokin, einen Neuropeptid-Präkursor oder mindestens ein Neuropeptid kodierende Nukleinsäuresequenz
DE10027383 2000-06-02
PCT/EP2001/006250 WO2001092530A1 (de) 2000-06-02 2001-06-01 Nukleinsäure-molekül umfassend eine für ein sdf-1 gamma chemokin, einen neuropeptid-präkursor oder mindestens ein neuropeptid kodierende nukleinsäuresequenz

Publications (1)

Publication Number Publication Date
AU6233501A true AU6233501A (en) 2001-12-11

Family

ID=7644466

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62335/01A Abandoned AU6233501A (en) 2000-06-02 2001-06-01 Nucleic acid molecule comprising a nucleic acid sequence coding for an sdf-1 gamma chemokine, a neuropeptide precursor or at least one neuropeptide

Country Status (9)

Country Link
US (2) US20030215792A1 (https=)
EP (1) EP1287142B1 (https=)
JP (1) JP2004521607A (https=)
AT (1) ATE309361T1 (https=)
AU (1) AU6233501A (https=)
DE (2) DE10027383A1 (https=)
DK (1) DK1287142T3 (https=)
ES (1) ES2251483T3 (https=)
WO (1) WO2001092530A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2522703A1 (en) * 2003-04-16 2004-11-04 Genebact Biotechnologies, Inc. Prophylactic and therapeutic benefits of new class of immune stimulating peptides
WO2006124013A2 (en) * 2004-04-30 2006-11-23 Five Prime Therapeutics, Inc. Novel stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof, and method of use
JP2009513689A (ja) * 2005-10-31 2009-04-02 ラボラトワール セローノ ソシエテ アノニム 神経学的疾患の治療、及び／又は予防のためのｓｄｆ−１の使用
WO2007119180A2 (en) * 2006-04-07 2007-10-25 Neuro Therapeutics Ab Survival and development of neural cells
US20090291887A1 (en) * 2006-07-07 2009-11-26 Mueller Hans-Werner Proteins of the SDF-1-Family for the Manufacturing of a Medicament
US7696309B2 (en) 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
EP2197907A2 (en) * 2007-10-15 2010-06-23 Centre National De La Recherche Scientifique-CNRS Cxcl12 gamma a chemokine and uses thereof
WO2011106234A1 (en) 2010-02-25 2011-09-01 Provasculon, Inc. Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
JP6145089B2 (ja) 2011-06-07 2017-06-07 メソブラスト インターナショナル エスエイアールエル ストロマ細胞由来因子−１のプロテアーゼ耐性変異体を用いた、組織損傷を修復するための方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5885794A (en) * 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
CA2117953C (en) * 1993-10-14 2001-12-11 Tasuku Honjo Human stromal derived factor 1 alpha and 1 beta and dnas encoding the same
CA2251603A1 (en) * 1996-04-10 1997-10-16 Axys Pharmaceuticals, Inc. Gene family associated with neurosensory defects
US6114502A (en) * 1996-04-10 2000-09-05 Axys Pharmaceuticals, Inc. Gene family associated with neurosensory defects
US6100387A (en) * 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
MXPA00003885A (es) * 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
AU3773099A (en) * 1998-04-29 1999-11-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Identification of polymorphisms in the pctg4 region of xq13
EP1100869A4 (en) * 1998-07-30 2005-04-27 Human Genome Sciences Inc 98 HUMAN SECRETED PROTEINS
CA2391814A1 (en) * 1999-12-16 2001-06-21 Ribotargets Limited Assays

Also Published As

Publication number Publication date
DE50108009D1 (de) 2005-12-15
DK1287142T3 (da) 2006-03-13
JP2004521607A (ja) 2004-07-22
WO2001092530A1 (de) 2001-12-06
ATE309361T1 (de) 2005-11-15
US20030215792A1 (en) 2003-11-20
US20080319165A1 (en) 2008-12-25
EP1287142A1 (de) 2003-03-05
EP1287142B1 (de) 2005-11-09
DE10027383A1 (de) 2001-12-20
ES2251483T3 (es) 2006-05-01

Similar Documents

Publication Publication Date Title
HUP0500345A2 (hu) Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
HUP0103758A2 (hu) Neurotróf faktorok
HUP0203409A2 (hu) Gamma-interferon-konjugátumok
MXPA02002384A (es) Polipeptidos similares al factor de crecimiento de fibroblastos.
WO2004037999A3 (en) A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
AU1724795A (en) Human tissue inhibitor of metalloproteinase-4
MXPA04001566A (es) Un sistema para expresion y ensamblado de anticuerpos.
WO2000053761A3 (en) Human cytokine as ligand of the zalpha receptor and uses thereof
WO1998035061A3 (en) Member of the tnf family useful for treatment and diagnosis of disease
AU6233501A (en) Nucleic acid molecule comprising a nucleic acid sequence coding for an sdf-1 gamma chemokine, a neuropeptide precursor or at least one neuropeptide
ATE70280T1 (de) Charakteristische polypeptide und antikoerper vom papillomavirus, diagnostische verfahren und dieselben verwendende impfungen.
DE69735207D1 (de) Neuartiges, fibrinogen-bindendes protein, welches von einem koagulase-negativen staphylokokkus abstammt
MY141459A (en) Recombinant anti-idiotypic antibodies
TR200103339T2 (tr) Geliştirilmiş çözülürlük özelliklerine sahip yeni LHRH-antagonistleri.
WO2003039591A3 (de) Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
AU2003240631A1 (en) A t cell subpopulation regulating gut immunity
DE60118359D1 (de) Humanische pellino-polypeptide
AR019864A1 (es) Proceso para producir el antigeno de toxoplasma sag1 o fragmentos del mismo; proteina sag1 o fragmentos de la misma expresada en dicho proceso;composiciones de vacuna que comprendan dicha proteina sag1 o fragmentos de la misma; uso de dicha proteina para la manufactura de medicamentos para preveniry
ATE554793T1 (de) Konjugat
EP0845535A3 (en) Leader peptidase (lep) from Streptococcus
TUINMAN et al. Analysis of the amino acid sequence of peptides by mass spectrometry an ion notation proposal
DE602004019141D1 (de) Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonin (ivtntt) enthaltende biologisch wirksame peptide
AU2806597A (en) Human DNase II
WO2003056341A3 (de) Verfahren zur diagnose von brustkrebserkrankungen, zugehörige peptide und deren verwendungen
PL359713A1 (en) Method for purifying recombinant proteins expressed as insoluble aggregates

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase